[go: up one dir, main page]

US11155839B2 - Recombinant bacteria for producing 3-hydroxy propionic acid, preparation method therefor, and applications thereof - Google Patents

Recombinant bacteria for producing 3-hydroxy propionic acid, preparation method therefor, and applications thereof Download PDF

Info

Publication number
US11155839B2
US11155839B2 US16/604,854 US201816604854A US11155839B2 US 11155839 B2 US11155839 B2 US 11155839B2 US 201816604854 A US201816604854 A US 201816604854A US 11155839 B2 US11155839 B2 US 11155839B2
Authority
US
United States
Prior art keywords
gene
seq
protein
sequence listing
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US16/604,854
Other languages
English (en)
Other versions
US20200157584A1 (en
Inventor
Weifeng Liu
Bo Liu
Qianqian CUI
Guang Zhao
Yong Tao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Microbiology of CAS
Original Assignee
Institute of Microbiology of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Microbiology of CAS filed Critical Institute of Microbiology of CAS
Assigned to INSTITUTE OF MICROBIOLOGY, CHINESE ACADEMY OF SCIENCES reassignment INSTITUTE OF MICROBIOLOGY, CHINESE ACADEMY OF SCIENCES ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: Cui, Qianqian, LIU, BO, LIU, WEIFENG, TAO, YONG, ZHAO, Guang
Publication of US20200157584A1 publication Critical patent/US20200157584A1/en
Application granted granted Critical
Publication of US11155839B2 publication Critical patent/US11155839B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/52—Propionic acid; Butyric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/06—Alanine; Leucine; Isoleucine; Serine; Homoserine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
    • C12P7/04—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
    • C12P7/18—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic polyhydric
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/42—Hydroxy-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/185—Escherichia
    • C12R2001/19—Escherichia coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
    • C12Y102/01075—Malonyl CoA reductase (malonate semialdehyde-forming)(1.2.1.75)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01041—Beta-ketoacyl-acyl-carrier-protein synthase I (2.3.1.41)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01179—Beta-ketoacyl-acyl-carrier-protein synthase II (2.3.1.179)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y604/00—Ligases forming carbon-carbon bonds (6.4)
    • C12Y604/01—Ligases forming carbon-carbon bonds (6.4.1)
    • C12Y604/01002—Acetyl-CoA carboxylase (6.4.1.2)

Definitions

  • the invention relates to recombinant bacteria for producing 3-hydroxypropionic acid, a preparation method therefor, and applications thereof in the technical field of biology.
  • 3-hydroxypropionic acid is an important chemical intermediate and platform compound with broad market prospects. It is also one of the 12 most promising bio-based chemical products in the world, listed by the U.S. Department of Energy in 2004. 3-hydroxypropionic acid not only may be used as an additive or preservative for food or feed, but also may synthesize various important chemicals, including acrylic acid, malonic acid, 1,3 propanediol, acrylamide, poly-3-hydroxypropionic acid and the like, through oxidation, dehydration, reduction, esterification, polymerization and other reactions.
  • the chemical methods for preparing 3-hydroxypropionic acid include a 3-hydroxynitrile hydrolysis method, a hydrated acrylic acid method, a 3-hydroxypropanal oxidation method, an allyl alcohol oxidation method, and the like.
  • the biological synthesis method of 3-hydroxypropionic acid mainly uses microbial fermentation to convert raw materials into 3-hydroxypropionic acid, or extracts related enzyme to produce 3-hydroxypropionic acid in a cell-free system.
  • the research on microbial synthesis of 3-hydroxypropionic acid mainly includes three aspects: (1) screening and mutagenizing microbial strains that naturally synthesize 3-hydroxypropionic acid; (2) constructing a recombinant microbial engineering strain to produce 3-hydroxypropionic acid using glucose; and (3) constructing a microbial engineering strain to produce 3-hydroxypropionic acid using glycerol.
  • Construction of the recombinant microbial engineering strains for synthesizing 3-hydroxypropionic acid using glucose as a substrate mainly includes Escherichia coli, Corynebacterium glutamicum and the like.
  • the synthesis of 3-hydroxypropionic acid by engineering strains mainly utilizes two types of synthetic pathways: (1) a synthetic pathway via 3-hydroxypropionyl-CoA; and (2) a synthetic pathway via malonyl-CoA.
  • Cargill Corporation, USA converts glucose to lactic acid using an engineering strain such as Escherichia coli based on the 3-hydroxypropionyl-CoA pathway, and then produces the 3-hydroxypropionic acid by a three-step reaction including catalysis by propionyl-CoA transferase, lactyl-CoA dehydratase, and 3-hydroxypropionyl hydrolase.
  • OPXBIO Inc., USA utilizes the malonyl-CoA pathway to convert a substrate to 3-hydroxypropionic acid by catalysis of acetyl-CoA carboxylase and malonyl-CoA reductase.
  • Construction of recombinant microbial engineering strains for the synthesis of 3-hydroxypropionic acid using glycerol as a substrate is carried out by oxidizing 3-hydroxypropionaldehyde into 3-hydroxypropionic acid mainly by introducing aldehyde oxidase in Klebsiella pneumoniae or Escherichia coli.
  • the main technical limitation of biosynthesis of 3-hydroxypropionic acid is that the raw material price is relatively high, and the theoretical conversion rate of the adopted pathway is low, and a new low-cost raw material rout urgently needs to be developed.
  • Fatty acids are a kind of substance with high degree of reduction.
  • the fatty acid raw materials used for microbial fermentation and biotransformation may be obtained at low prices from sources such as crude oil processing products and waste oil.
  • the technical problem to be solved by the present invention is how to produce 3-hydroxypropionic acid.
  • the present invention provides a construction method of recombinant bacteria at first.
  • the construction method of the recombinant bacteria provided by the present invention includes: modifying recipient bacteria by A or B to obtain the recombinant bacteria; the A being A6; the B being A6 and all or part of A1, A2, A3, A4, A5, A7 and A8;
  • A1 knocking out a fatty acid degradation transcription factor fadR gene of the recipient bacteria or inhibiting expression of the fadR gene or inhibiting activity of a protein encoded by the fadR gene;
  • A4 increasing content of a protein encoded by an acetyl-CoA carboxylase acc gene or gene cluster in the recipient bacteria or/and enhancing activity of the protein encoded by the acc gene or gene cluster;
  • A6 increasing content of a protein encoded by a malonyl-CoA reductase gene mcr gene in the recipient bacteria or/and enhancing activity of the protein encoded by the mcr gene;
  • the recipient bacteria being bacteria or fungi containing the fadR gene, the fabF gene, and the fabH gene.
  • the recipient bacteria may be 1) or 2):
  • the acc gene or gene cluster may be derived from Corynebacterium glutamicum or/and Rhodococcus opacus.
  • the alkL gene may be derived from Marinobacter hydrocarbonoclasticus or/and Pseudomonas putida.
  • the mcr gene may be derived from Chloroflexus aurantiacus.
  • the fadR gene may encode a protein of the following a1) or a2):
  • a2) a protein having 75% or higher identity with an amino acid sequence of SEQ ID No. 2 and having a same function, obtained by substitution and/or deletion and/or addition of one or more amino acid residues in the amino acid sequence of SEQ ID No. 2 in the sequence listing.
  • the fabF gene may encode a protein of the following a3) or a4):
  • a4 a protein having 75% or higher identity with an amino acid sequence of SEQ ID No. 14 and having a same function, obtained by substitution and/or deletion and/or addition of one or more amino acid residues in the amino acid sequence of SEQ ID No. 14 in the sequence listing.
  • the fabH gene may encode a protein of the following a5) or a6):
  • a6 a protein having 75% or higher identity with an amino acid sequence of SEQ ID No. 16 and having a same function, obtained by substitution and/or deletion and/or addition of one or more amino acid residues in the amino acid sequence of SEQ ID No. 16 in the sequence listing.
  • the acc gene or gene cluster may encode proteins of a7) and a8):
  • a72 a protein having 75% or higher identity with an amino acid sequence of SEQ ID No. 26 and having a same function, obtained by substitution and/or deletion and/or addition of one or more amino acid residues in the amino acid sequence of SEQ ID No. 26 in the sequence listing;
  • a82 a protein having 75% or higher identity with an amino acid sequence of SEQ ID No. 27 and having a same function, obtained by substitution and/or deletion and/or addition of one or more amino acid residues in the amino acid sequence of SEQ ID No. 27 in the sequence listing.
  • the alkL gene may encode a protein of the following a9) or a10):
  • the mcr gene may encode a protein of the following a11) or a12):
  • a12 a protein having 75% or higher identity with an amino acid sequence of SEQ ID No. 37 and having a same function, obtained by substitution and/or deletion and/or addition of one or more amino acid residues in the amino acid sequence of SEQ ID No. 37 in the sequence listing.
  • A4 may be achieved by introducing the acc gene or gene cluster into the recipient bacteria.
  • A5 may be achieved by introducing the alkL gene into the recipient bacteria.
  • A6 may be achieved by introducing the mcr gene into the recipient bacteria.
  • introducing the acc gene or gene cluster into the recipient bacteria may specifically be introducing an expression vector (i.e., an acc gene or a gene cluster expression vector) containing the acc gene or gene cluster into the recipient bacteria.
  • an expression vector i.e., an acc gene or a gene cluster expression vector
  • Introducing the alkL gene into the recipient bacteria may specifically be introducing an expression vector (i.e., an alkL gene expression vector) containing the alkL gene into the recipient bacteria.
  • an expression vector i.e., an alkL gene expression vector
  • Introducing the mcr gene into the recipient bacteria may specifically be introducing an expression vector (i.e., an mcr gene expression vector) containing the mcr gene into the recipient bacteria.
  • an expression vector i.e., an mcr gene expression vector
  • the expression vector may be a plasmid, a cosmid, a phage or a viral vector.
  • the plasmid may specifically be pSB1s or pXB1k, the sequence of the pSB1s is SEQ ID No. 30 in the sequence listing, and the sequence of the pXB1k is SEQ ID No. 35 in the sequence listing.
  • a single expression vector may be introduced, or a co-expression vector may be introduced.
  • the single expression vector contains only one of the acc gene or gene cluster, the alkL gene, and the mcr gene.
  • the co-expression vector contains at least two of the acc gene or gene cluster, the alkL gene, and the mcr gene.
  • introduction of the acc gene or gene cluster and the alkL gene into the recipient bacteria is realized by introducing a co-expression vector (i.e., an acc-alkL co-expression vector) containing the two genes or gene clusters into the recipient bacteria, and introduction of the mcr gene into the recipient bacteria is realized by introducing a single expression vector (i.e., an mcr expression vector) containing the gene into the recipient bacteria.
  • the acc-alkL co-expression vector may specifically be a recombinant vector pSB1s-acc-alkL obtained by introducing the acc gene or gene cluster and the alkL gene into the pSB1s.
  • the pSB1s-acc-alkL may express the accBC protein shown in SEQ ID No. 26, the accDA protein shown in SEQ ID No. 27, and the alkL protein shown in SEQ ID No. 29.
  • the mcr expression vector may specifically be a recombinant vector pXB1k-mcr obtained by introducing the mcr gene into the pXB1k.
  • the pXB1k-mcr may express the mcr protein shown in SEQ ID No. 37.
  • the fadR gene may be the following b1) or b2):
  • b2) a cDNA molecule or genomic DNA molecule having 75% or higher identity with a nucleotide sequence defined by b1) and having a same function.
  • the fabF gene may be the following b3) or b4):
  • b4) a cDNA molecule or genomic DNA molecule having 75% or higher identity with a nucleotide sequence defined by b3) and having a same function.
  • the fabH gene may be the following b5) or b6):
  • b6) a cDNA molecule or genomic DNA molecule having 75% or higher identity with a nucleotide sequence defined by b5) and having a same function.
  • the acc gene or gene cluster may be the following b7) or b8):
  • b8) a cDNA molecule or genomic DNA molecule having 75% or higher identity with a nucleotide sequence defined by b7) and having a same function.
  • the alkL gene may be the following b9) or b10):
  • b10) a cDNA molecule or genomic DNA molecule having 75% or higher identity with a nucleotide sequence defined by b9) and having a same function.
  • the mcr gene may be the following b11) or b12):
  • b12 a cDNA molecule or genomic DNA molecule having 75% or higher identity with a nucleotide sequence defined by b11) and having a same function.
  • knockout of the fatty acid degrading transcription factor fadR gene of the recipient bacteria in A1 may be carried out by homologous recombination, and specifically, an Escherichia coli strain JW1176 having a fadR gene knockout trait may be used.
  • Knockout of the ⁇ -ketoacyl-ACP synthase II gene fabF gene of the recipient bacteria in A2 may be carried out by homologous recombination, and specifically, an Escherichia coli strain JW1081 having a fabF gene knockout trait may be used.
  • Knockout of the ⁇ -ketoacyl-ACP synthase III gene fabH gene of the recipient bacteria in A3 may be carried out by homologous recombination, and specifically, an Escherichia coli strain JW1077 having a fabH gene knockout trait may be used.
  • the above method may further include four, any three, any two or any one of the following B1-B4:
  • the gene in the fatty acid ⁇ oxidation pathway being selected from one or more of the following genes: a fadD gene encoding fatty acyl-CoA synthase, a fadE gene encoding fatty acyl-CoA dehydrogenase, a fadB gene encoding 3-hydroxyacyl-CoA dehydrogenase, a fadA gene encoding 3-ketoacyl-CoA thiolase, a fadI gene encoding 3-ketoacyl-CoA thiolase, a fadJ gene encoding 3-hydroxyacyl-CoA dehydrogenase and a fadK gene encoding short-chain fatty acyl-CoA synthase;
  • the gene in the short-chain fatty acid degradation pathway is B4a or B4b:
  • B4a a gene in a short-chain fatty acid degradation regulatory gene cluster atoSC gene cluster
  • B4b a gene in a short-chain fatty acid degradation gene cluster atoDAEB gene cluster.
  • the recipient bacteria may further contain the fadL gene, the gene in the fatty acid ⁇ oxidation pathway, the sthA gene, and/or the gene in the short-chain fatty acid degradation pathway.
  • the gene in the short-chain fatty acid degradation regulatory gene cluster atoSC gene cluster may be a gene atoC gene encoding an atoC transcription activator and/or a gene atoS gene encoding atoS-sensing histidine kinase.
  • the gene in the short-chain fatty acid degradation gene cluster atoDAEB gene cluster may be a gene atoA gene encoding an acetoacetyl-CoA transferase ⁇ subunit, a gene atoD gene encoding an acetoacetyl-CoA transferase ⁇ subunit, a gene atoE gene encoding an acetoacetic acid transport protein, and/or a gene atoB gene encoding an acetyl-CoA acetyltransferase.
  • the fadL gene may encode a protein of the following a17) or a18):
  • a18 a protein having 75% or higher identity with an amino acid sequence of SEQ ID No. 6 and having a same function, obtained by substitution and/or deletion and/or addition of one or more amino acid residues in the amino acid sequence of SEQ ID No. 6 in the sequence listing.
  • the fadD gene may encode a protein of the following a19) or a20):
  • a20 a protein having 75% or higher identity with an amino acid sequence of SEQ ID No. 9 and having a same function, obtained by substitution and/or deletion and/or addition of one or more amino acid residues in the amino acid sequence of SEQ ID No. 9 in the sequence listing.
  • the sthA gene may encode a protein of the following a21) or a22):
  • a22 a protein having 75% or higher identity with an amino acid sequence of SEQ ID No. 12 and having a same function, obtained by substitution and/or deletion and/or addition of one or more amino acid residues in the amino acid sequence of SEQ ID No. 12 in the sequence listing.
  • the atoSC gene cluster may encode proteins of the following a23) and a24):
  • a23 a protein of the following a231) or a232):
  • a232 a protein having 75% or higher identity with an amino acid sequence of SEQ ID No. 19 and having a same function, obtained by substitution and/or deletion and/or addition of one or more amino acid residues in the amino acid sequence of SEQ ID No. 19 in the sequence listing;
  • a24 a protein of the following a241) or a242):
  • a242 a protein having 75% or higher identity with an amino acid sequence of SEQ ID No. 21 and having a same function, obtained by substitution and/or deletion and/or addition of one or more amino acid residues in the amino acid sequence of SEQ ID No. 21 in the sequence listing.
  • B1 may be achieved by substituting a promoter P CPA1 for a promoter of the fadL gene.
  • B2 may be achieved by substituting the promoter P CPA1 for a promoter of the gene in the fatty acid ⁇ oxidation pathway.
  • B3 may be achieved by substituting the promoter P CPA1 for a promoter of the sthA gene.
  • B4 may be achieved by substituting the promoter P CPA1 for a promoter of the gene in the short-chain fatty acid degradation pathway.
  • the promoter of the gene in the short-chain fatty acid degradation pathway may be a promoter of the short-chain fatty acid degradation regulatory gene cluster or a promoter of the short-chain fatty acid degradation gene cluster atoDAEB gene cluster.
  • the promoter P CPA1 may be a nucleic acid molecule of the following 1) or 2) or 3):
  • substitution of the promoter PP CPA1 for the promoter of the fadL gene may be achieved by a DNA fragment shown in SEQ ID No. 4 in the sequence listing.
  • Substitution of the promoter P CPA1 for the promoter of the gene in the fatty acid ⁇ oxidation pathway may be achieved by a DNA fragment shown in SEQ ID No. 7 in the sequence listing.
  • Substitution of the promoter P CPA1 for the promoter of the sthA gene may be achieved by a DNA fragment shown in SEQ ID No. 10 in the sequence listing.
  • Substitution of the promoter P CPA1 for the promoter of the gene in the short-chain fatty acid degradation pathway may be achieved by a DNA fragment shown in SEQ ID No. 17 in the sequence listing.
  • the 75% or higher identity may be 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher identity.
  • the present invention also provides a preparation method for the 3-hydroxypropionic acid.
  • the preparation method for the 3-hydroxypropionic acid provided by the present invention includes: bio-transforming the recombinant bacteria prepared by the preparation method of the recombinant bacteria with fatty acid as a substrate to prepare the 3-hydroxypropionic acid.
  • the fatty acid may be palmitic acid, stearic acid, myristic acid, lauric acid, capric acid, octanoic acid and/or hexanoic acid.
  • the above preparation method for the 3-hydroxypropionic acid may further include inducing the recombinant bacteria with arabinose prior to the biotransformation.
  • the above preparation method for the 3-hydroxypropionic acid may specifically be preparation of the 3-hydroxypropionic acid by whole cell catalysis of the fatty acid by using the recombinant bacteria.
  • the present invention also provides any one of the following Z1-Z4 products:
  • Mia and M1b being a protein encoded by the mcr gene, and M1b being a11 or part of a protein encoded by the acc gene or gene cluster and a protein encoded by the alkL gene;
  • M2a being a11 or part of a protein encoded by the fadL gene, a protein encoded by the fadD gene, a protein encoded by the sthA gene, and a protein encoded by the atoSC gene cluster;
  • N1a and N1b, N1a being the mcr gene, and N1b being a11 or part of the acc gene or gene cluster and the alkL gene;
  • N2a being a11 or part of the fadL gene, the fadD gene, the sthA gene, and the atoSC gene cluster;
  • a set of reagents consisting of the promoter P CPA1 and the gene or the set of genes.
  • the present invention also provides any one of the following uses of the products:
  • FIG. 1 shows production of ⁇ -alanine using FM08.
  • FIG. 2 shows production of 3-hydroxypropionic acid using FI08.
  • FIG. 3 shows production of ⁇ -alanine using FA11.
  • Escherichia coli BW25113 (Datsenko K A, Wanner B L. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc. Natl. Acad. Sci. U.S.A. 2,000; 97(12):6640-6645) is non-pathogenic bacteria with a clear genetic background, short generation time, easy cultivation, and low-price culture medium raw materials.
  • the Escherichia coli BW25113 is available to the public from the Institute of Microbiology, Chinese Academy of Sciences. The biomaterial is used only for repeating the relevant experiments of the present invention and cannot be used for other purposes.
  • a basic strain FM07 which may be used for preparing a strain for producing ⁇ -alanine and 3-hydroxypropionic acid was prepared.
  • a preparation method of the strain was as follows, and primers used were shown in Table 1.
  • the Escherichia coli gene fragment having the fadR knockout trait was derived from an Escherichia coli strain JW1176.
  • the strain was a W3110 series strain having the fadR knockout trait.
  • JW1176 was a product of the National Institute of Genetics (NIG, Japan).
  • a kanamycin resistance gene (about 1300 bp) with an FRT site at two ends was substituted for a gene fadR encoding a fatty acid degradation transcription factor to knock out the fadR gene.
  • the preparation process of the P1 phage was as follows: a JW1176 strain was cultured overnight at 37° C., and then transferred to an LB medium containing 5 mmol/L CaCl 2 and 0.1% glucose and cultured for 1 h at 37° C., then a wild type P1 phage was added and culture was continued for 1-3 h, a few drops of chloroform were added for further culture for a few minutes, and a supernatant was obtained by centrifuging to obtain a phage P1vir fadR containing the Escherichia coli gene fragment having the fadR knockout trait.
  • the bacterial cells were collected by centrifugation. After being resuspended in 100 ⁇ L of LB medium, the bacterial cells were spread on LB plates containing kanamycin (the concentration of kanamycin was 50 ⁇ g/ml). After culturing overnight at 37° C., clones were selected.
  • the fadR-IF/fadR-IR primer was used for PCR amplification and identification (an amplified target band of 1700 bp was positive), and positive clones were selected and named FM01-Kan.
  • the pCP20 plasmid (Clontech Company) was transformed into FM01-Kan by a calcium chloride transformation method, the FM01-Kan was cultured overnight at 30° C. in an LB plate containing ampicillin, and then clones were selected to obtain recombinant Escherichia coli FM01-Kan/pCP20 containing the plasmid pCP20. After being cultured in an LB medium containing ampicillin resistance at 30° C., the cells were spread on a non-resistant LB plate and cultured at 43° C. overnight, and clones were selected.
  • the fadR-IF/fadR-IR primer was used for PCR amplification and identification (an amplified target band of 400 bp was positive), and positive clones were selected and named FM01.
  • FM01 is a strain obtained by knocking out the fatty acid degradation transcription factor fadR gene of Escherichia coli BW25113.
  • the fadR gene encodes the protein shown in SEQ ID No. 2, and the coding sequence of the fadR gene is shown in SEQ ID No. 1.
  • FadR-IF/fadR-IR obtains a fragment of about 400 bp by amplification from the genomic DNA of FM01, and obtains a fragment of about 1100 bp by amplification from the genomic DNA of Escherichia coli BW25113.
  • the primer binding positions of the fadR-IF and fadR-IR are the upstream region and the downstream region of the fadR gene of Escherichia coli BW25113, respectively.
  • the results of sequencing analysis show that there is no fadR gene in the genome of FM01, and FM01 is a mutant of Escherichia coli BW25113 obtained by knocking out the fadR gene of Escherichia coli BW25113.
  • the pKD46 plasmid (Clontech Company) was transformed into the FM01 strain obtained in the previous step by a calcium chloride transformation method, the strain was cultured overnight at 30° C. in an LB plate containing ampicillin, and then clones were selected to obtain recombinant Escherichia coli FM01/pKD46 containing the plasmid pKD46.
  • the recombinant Escherichia coli FM01/pKD46 expressed three recombinant proteins of ⁇ phage after arabinose induction, and the host bacteria had the ability of homologous recombination.
  • FM01/pKD46 competent cells were then prepared by washing with 10% glycerol.
  • CPA1-Lox66-Kan-Lox71 contained: A. a constitutive promoter P CPA1 sequence, the nucleotide sequence of which was positions 1443-1622 of SEQ ID No. 3, and B. a kanamycin resistance gene (LOXP-kan-LOXP) flanked by LOXP, the nucleotide sequence of which was positions 21-1433 of SEQ ID No. 3.
  • the CPA1-Lox66-Kan-Lox71 sequence was ligated to a pUC57 vector by whole gene synthesis (Nanjing Genscript Biotechnology Co., Ltd.) to obtain a recombinant vector pUC57-9K.
  • a fadLup-kan-P CPA1 -fadLdown fragment was amplified using a primer fadL-PF/fadL-PR.
  • the sequence of the fadLup-kan-P CPA1 -fadLdown fragment was SEQ ID No. 4 in the sequence listing, and the fragment contains (a) a promoter upstream homologous arm fadLup of the fadL gene, the nucleotide sequence of which was positions 1-51 of SEQ ID No.
  • LOXP-kan-LOXP kanamycin resistance gene flanked by LOXP, the nucleotide sequence of which was positions 52-1492 of SEQ ID No. 4
  • LOXP-kan-LOXP kanamycin resistance gene flanked by LOXP
  • an Escherichia coli constitutive promoter P CPA1 the nucleotide sequence of which was positions 1493-1670 of SEQ ID No. 4
  • a promoter downstream homologous arm fadLdown of the fadL gene the nucleotide sequence of which was positions 1671-1722 of SEQ ID No. 4.
  • the above fadLup-kan-P CPA1 -fadLdown fragment was electroporated into the FM01/pKD46 competent cells prepared in (2-a), the cells were placed in an LB plate containing kanamycin (concentration: 50 ⁇ g/ml) overnight at 37° C., and clones were selected.
  • a fadL-PIF/fadL-PIR primer was used for PCR amplification and identification (an amplified target band of about 2,000 bp was positive, and an amplified target band of about 400 bp was negative), and positive clones were selected and named FM02-kan.
  • the primer binding positions were the upstream and downstream regions of the promoter of the fadL gene of Escherichia coli BW25113, respectively.
  • the results of sequencing analysis indicate that an FM02-kan genome contains the fadLup-kan-P CPA1 -fadLdown fragment of the step (2-c).
  • the pCP20 plasmid (Clontech Company) was transformed into FM02-Kan by a calcium chloride transformation method, the FM02-Kan was cultured overnight at 30° C. in an LB plate containing ampicillin, and then clones were selected to obtain recombinant Escherichia coli FM02-Kan/pCP20 containing the plasmid pCP20. After being cultured in an LB medium containing ampicillin resistance at 30° C., the cells were spread on a non-resistant LB plate and cultured at 43° C. overnight, and clones were selected.
  • the fadL-PIF/fadL-PIR primer was used for PCR amplification and identification (an amplified target band of about 600 bp was positive, and an amplified target band of about 2,000 bp or 400 bp was negative), and positive clones were selected and named FM02.
  • FM02 is a strain obtained by substituting the constitutive promoter P CPA1 for a promoter of a fadL gene of FM01.
  • the fadL gene encodes the protein shown in SEQ ID No. 6, and the coding sequence of the fadL gene is shown in SEQ ID No. 5.
  • the results of sequencing analysis indicate that the constitutive promoter P CPA1 is substituted for the fadL gene promoter on the genome of FM02, and expression of the fadL gene is initiated by P CPA1 .
  • the Escherichia coli constitutive promoter P CPA1 was substituted for a promoter of a fatty acyl-CoA synthase fadD gene in the strain, and recombinant Escherichia coli FM03 was obtained.
  • the specific steps were as follows:
  • the pKD46 plasmid was transformed into the FM02 strain obtained in the previous step according to the method of the step (2) to obtain recombinant Escherichia coli FM02/pKD46 containing the plasmid pKD46, and then FM02/pKD46 competent cells were prepared.
  • a fadD-kan-P CPA1 -fadDdown fragment was amplified using a primer fadD-PF/fadD-PR.
  • the sequence of the fadDup-kan-P CPA1 -fadDdown fragment was SEQ ID No. 7 in the sequence listing, and the fragment contained (a) a promoter upstream homologous arm fadDup of the fadD gene, the nucleotide sequence of which was positions 1-51 of SEQ ID No.
  • LOXP-kan-LOXP kanamycin resistance gene flanked by LOXP, the nucleotide sequence of which was positions 52-1492 of SEQ ID No. 7
  • LOXP-kan-LOXP kanamycin resistance gene flanked by LOXP
  • an Escherichia coli constitutive promoter P CPA1 the nucleotide sequence of which was positions 1493-1670 of SEQ ID No. 7
  • a promoter downstream homologous arm fadDdown of the fadD gene the nucleotide sequence of which was positions 1671-1722 of SEQ ID No. 7.
  • the above fadDup-kan-P CPA1 -fadDdown fragment was electroporated into the FM02/pKD46 competent cells prepared in (3-a), the cells were placed in an LB plate containing kanamycin (concentration: 50 ⁇ g/ml) overnight at 37° C., and clones were selected.
  • a fadD-PIF/fadD-PIR primer was used for PCR amplification and identification (an amplified target band of 2,000 bp was positive, and an amplified target band of about 400 bp in length was negative), and positive clones were selected and named FM03-kan.
  • the primer binding positions were the upstream and downstream regions of the promoter of the fadD gene of Escherichia coli BW25113, respectively.
  • the results of sequencing analysis indicate that an FM03-kan genome contains the fadDup-kan-P CPA1 -fadDdown fragment of the step (3-b).
  • the kanamycin resistance of FM03-kan was eliminated using the pCP20 plasmid according to the method of the step (2).
  • the fadD-PIF/fadD-PIR primer was used for PCR amplification and identification (an amplified target band of about 600 bp was positive, and an amplified target band of about 2,000 bp or 400 bp was negative), and positive clones were selected and named FM03.
  • FM03 is a strain obtained by substituting the constitutive promoter P CPA1 for the promoter of the fadD gene of FM02.
  • the fadD gene encodes the protein shown in SEQ ID No. 9, and the coding sequence of the fadD gene is shown in SEQ ID No. 8.
  • the results of sequencing analysis indicate that the constitutive promoter P CPA1 is substituted for the fadD gene promoter on the genome of FM03, and the expression of the fadD gene is initiated by P CPA1 .
  • the Escherichia coli constitutive promoter P CPA1 was substituted for a promoter of a fatty acyl-CoA synthase sthA gene in the strain, and recombinant Escherichia coli FM04 was obtained.
  • the specific steps were as follows:
  • the pKD46 plasmid was transformed into the FM03 strain obtained in the previous step according to the method of the step (2) to obtain recombinant Escherichia coli FM03/pKD46 containing the plasmid pKD46, and then FM03/pKD46 competent cells were prepared.
  • a sthAup-kan-P CPA1 -sthAdown fragment was amplified using a primer sthA-PF/sthA-PR.
  • the sequence of the sthAup-kan-P CPA1 -sthAdown fragment was SEQ ID No. 10 in the sequence listing, and the fragment contained (a) a promoter upstream homologous arm fadDup of the sthA gene, the nucleotide sequence of which was positions 1-51 of SEQ ID No.
  • the above sthAup-kan-P CPA1 -sthAdown fragment was electroporated into the FM03/pKD46 competent cells prepared in (4-a), the cells were placed in an LB plate containing kanamycin (concentration: 50 ⁇ g/ml) overnight at 37° C., and clones were selected.
  • a sthA-PIF/sthA-PIR primer was used for PCR amplification and identification (an amplified target band of 2,000 bp was positive, and an amplified target band of about 400 bp was negative), and positive clones were selected and named FM04-kan.
  • the primer binding positions were the upstream and downstream regions of the promoter of the sthA gene of Escherichia coli BW25113, respectively.
  • the results of sequencing analysis indicate that the genome of FM04-kan contains the sthAup-kan-P CPA1 -sthAdown fragment of the step (4-b).
  • the kanamycin resistance of FM04-kan was eliminated using the pCP20 plasmid according to the method of the step (2).
  • the sthA-PIF/sthA-PIR primer was used for PCR amplification and identification (an amplified target band of about 600 bp was positive, and an amplified target band of about 2,000 bp or 400 bp was negative), and positive clones were selected and named FM04.
  • FM04 is a strain obtained by substituting the constitutive promoter P CPA1 for the promoter of the sthA gene of FM03.
  • the sthA gene encodes the protein shown in SEQ ID No. 12, and the coding sequence of the sthA gene is shown in SEQ ID No. 11.
  • the results of sequencing analysis indicate that the constitutive promoter P CPA1 is substituted for the sthA gene promoter on the genome of FM04, and the expression of the sthA gene is initiated by P CPA1 .
  • the Escherichia coli gene fragment having the fabF knockout trait was derived from Escherichia coli strain JW1081.
  • JW1081 was a product of the National Institute of Genetics (NIG, Japan). According to the P1 phage preparation method of the step (1), the strain JW1081 was substituted for the JW1176 strain, and the phage P1vir fabF containing the Escherichia coli gene fragment having the fabF knockout trait was obtained.
  • the FM04 of the step (4) was substituted for the Escherichia coli BW25113.
  • a fabF-IF/fabF-IR primer was used for PCR amplification and identification (an amplified target band of about 1700 bp was positive), and positive clones were selected and named FM05-Kan.
  • FM05-Kan was substituted for FM01-Kan, and the kanamycin resistance of the strain was eliminated.
  • the fabF-IF/fabF-IR primer was used for PCR amplification and identification (an amplified target band of 400 bp was positive), and positive clones were selected and named FM05.
  • FM05 is a strain obtained by knocking out the fabF gene of FM04.
  • the fabF gene encodes the protein shown in SEQ ID No. 14, and the coding sequence of the fabF gene is shown in SEQ ID No. 13.
  • FadF-IF/fadF-IR obtains a fragment of about 400 bp by amplification from the genomic DNA of FM05, and obtains a fragment of about 1600 bp by amplification from the genomic DNA of FM04.
  • the fabF-IF and fabF-IR primer binding positions are the upstream region and the downstream region of the fabF gene of Escherichia coli BW25113, respectively.
  • the results of sequencing analysis show that there is no fabF gene in the genome of FM05, and FM05 is a strain obtained by knocking out the fabF gene of FM04.
  • the Escherichia coli gene fragment having the fabH knockout trait was derived from Escherichia coli strain JW1077.
  • JW1077 was a product of the National Institute of Genetics (NIG, Japan). According to the P1 phage preparation method of the step (1), the strain JW1077 was substituted for the JW1176 strain, and the phage P1vir fabH containing the Escherichia coli gene fragment having the fabH knockout trait was obtained.
  • the FM05 of the step (4) was substituted for the Escherichia coli BW25113.
  • a fabH-IF/fabH-IR primer was used for PCR amplification and identification (an amplified target band of about 1700 bp was positive), and positive clones were selected and named FM06-Kan.
  • FM06-Kan was substituted for FM01-Kan, and the kanamycin resistance of the strain was eliminated.
  • the fabH-IF/fabH-IR primer was used for PCR amplification and identification (an amplified target band of about 400 bp was positive), and positive clones were selected and named FM06.
  • FM06 is a strain obtained by knocking out the fabH gene of FM05.
  • the fabH gene encodes the protein shown in SEQ ID No. 16, and the coding sequence of the fabH gene is shown in SEQ ID No. 15.
  • FabH-IF/fabH-IR obtains a fragment of about 400 bp by amplification from the genomic DNA of FM06, and obtains a fragment of about 1400 bp by amplification from the genomic DNA of FM05.
  • the fabH-IF and fabH-IR primer binding positions are the upstream region and the downstream region of the fabH gene of Escherichia coli BW25113, respectively.
  • the results of sequencing analysis show that there is no fabH gene in the genome of FM06, and FM06 is a strain obtained by knocking out the fabH gene of FM05.
  • the Escherichia coli constitutive promoter P CPA1 was substituted for the promoter of the short-chain fatty acid degradation regulatory gene cluster atoSC (the gene cluster contained the atoS gene and the atoC gene), and recombinant Escherichia coli FM07 was obtained.
  • the specific steps were as follows:
  • the pKD46 plasmid was transformed into the FM06 strain obtained in the previous step according to the method of the step (2) to obtain recombinant Escherichia coli FM06/pKD46 containing the plasmid pKD46, and then FM06/pKD46 competent cells were prepared.
  • an atoSCup-kan-PCPA1-atoSCdown fragment was amplified using a primer atoSC-PF/atoSC-PR.
  • the sequence of the atoSCup-kan-P CPA1 -atoSCdown fragment was SEQ ID No. 17 in the sequence listing, and the fragment contained (a) a promoter upstream homologous arm atoSCup of the atoSC gene cluster, the nucleotide sequence of which was positions 1-51 of SEQ ID No. 17; (b) a kanamycin resistance gene (LOXP-kan-LOXP) flanked by LOXP, the nucleotide sequence of which was positions 52-1492 of SEQ ID No.
  • LOXP-kan-LOXP kanamycin resistance gene flanked by LOXP
  • the above atoSCup-kan-P CPA1 -atoSCdown fragment was electroporated into the FM06/pKD46 competent cells prepared in (7-a), the cells were placed in an LB plate containing kanamycin (concentration: 50 ⁇ g/ml) overnight at 37° C., and clones were selected.
  • An atoSC-PIF/atoSC-PIR primer was used for PCR amplification and identification (an amplified target band of 2,000 bp was positive, and an amplified target band of 400 bp was negative), and positive clones were selected and named FM07-kan.
  • the primer binding positions were the upstream and downstream regions of a promoter of the atoSC gene cluster of Escherichia coli BW25113, respectively.
  • the results of sequencing analysis indicate that the genome of FM07-kan contains the atoSCup-kan-P CPA1 -atoSCdown fragment of the step (7-b).
  • the kanamycin resistance of FM07-kan was eliminated using the pCP20 plasmid according to the method of the step (2).
  • the atoSC-PIF/atoSC-PIR primer was used for PCR amplification and identification (an amplified target band of about 600 bp was positive, and an amplified target band of about 2,000 bp or 400 bpbp was negative), and positive clones were selected and named FM07.
  • FM07 is a strain obtained by substituting the constitutive promoter P CPA1 for the promoter of the atoSC gene cluster of FM06.
  • the atoS gene in the atoSC gene cluster encodes the protein shown in SEQ ID No. 19
  • the coding sequence of the atoS gene is shown in SEQ ID No. 18
  • the atoC gene encodes the protein shown in SEQ ID No. 21, and the coding sequence of the atoC gene is shown in SEQ ID No. 20.
  • the results of sequencing analysis indicate that the constitutive promoter P CPA1 is substituted for the promoter of the atoSC gene cluster on the genome of FM07, and the expression of the atoS gene and the atoC gene in the atoSC gene cluster is initiated by P CPA1 .
  • a preparation method of FM08 was as follows, and primers used were shown in Table 2.
  • the nucleotide sequence of the modified Chloroflexus aurantiacus malonyl-CoA reductase truncation gene mcrC was shown in SEQ ID No. 22, and the mcrC gene encoded the protein shown in SEQ ID No. 23 in the sequence listing.
  • the mcrC gene shown in SEQ ID No. 22 was gene-synthesized, and then the mcrC gene shown in SEQ ID No. 22 was ligated to the pUC57 vector by a Gibson assembly method (Gibson D G, Young L, et al. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat. methods.
  • a vector pLB1a (the nucleotide sequence of the vector pLB1a was shown in SEQ ID No. 24) was digested with NcoI and XhoI, and a large fragment LB1a-NX of the vector was recovered.
  • the mcrC gene fragment with the correct sequence obtained in the above (1-a) was ligated with the LB1a-NX fragment by the Gibson assembly method.
  • Escherichia coli DH5 ⁇ competent cells were transformed by a CaCl 2 method (Beijing TransGen Biotech Co., Ltd., product catalogue: CD201). The cells were spread on an LB plate containing ampicillin and cultured overnight at 37° C.
  • Clones were selected and identified by a primer F105-F/mcrC-R.
  • the positive clones with the correct sequence of the target fragment were selected, and the obtained positive recombinant plasmid was named pLB1a-mcrC.
  • the Corynebacterium glutamicum acetyl-CoA carboxylase acc gene cluster was gene-synthesized and ligated to the pUC57 vector by the Gibson assembly method to obtain a vector pUC57-acc.
  • the nucleotide sequence of the acc gene cluster was shown in SEQ ID No. 25.
  • the sequence of the RBS1 site preceding the accBC gene was positions 2-7 of SEQ ID No. 25.
  • the nucleotide sequence of accBC was positions 15-1790 of SEQ ID No. 25, and the amino acid sequence was SEQ ID No. 26.
  • the nucleotide sequence of accDA was positions 1805-3259 of SEQ ID No. 25, and the amino acid sequence was SEQ ID No. 27.
  • the RBC2 site was contained between the accBC and accDA sequences, and the sequence was positions 1792-1797 of SEQ ID No. 25.
  • acc-F and acc-R as a primers and the vector pUC57-acc as a template, the acc gene fragment with the correct sequence was amplified by PCR using high-fidelity TransStart FastPfu DNA polymerase.
  • the plasmid pLB1a-mcrC of the step (1) was digested with XhoI and EcoRI to obtain a large fragment LB1a-mcrC-XE.
  • the above acc gene fragment was ligated with the LB1a-mcrC-XE fragment by the Gibson assembly method.
  • Escherichia coli DH5a competent cells were transformed by the CaCl 2 method. The cells were spread on an LB plate containing ampicillin and cultured overnight at 37° C. Clones were selected and identified by a primer acc-F/T58-R. The positive clones with the correct sequence of the target fragment were selected and the obtained positive recombinant plasmid was named pLB1a-mcrC-acc.
  • the genomic DNA of Marinobacter hydrocarbonoclasticus was extracted using a bacterial genome extraction kit (Tiangen Biotech Co., Ltd., product catalogue: DP302). Using the extracted total DNA of the Marinobacter hydrocarbonoclasticus genome as a template, the alkL gene fragment was amplified by PCR with a primer alkL-F/alkL-R, and an RBS sequence was introduced into the primer.
  • the vector pLB1a-mcrC-acc obtained by the step (2) was digested with EcoRI and PstI to obtain a large fragment LB1a-mcrC-acc-EP.
  • the above alkL gene fragment was ligated with the LB1a-mcrC-acc-EP fragment by the Gibson assembly method.
  • Escherichia coli DH5a was transformed and identified with a primer alkL-F/T58-R. Positive clones with the correct sequence of the target fragment were selected, and the obtained positive recombinant plasmid was named pLB1a-mcrC-acc-alkL.
  • PLB1a-mcrC-acc-alkL contains the mcrC gene shown in SEQ ID No. 22, the acc gene cluster shown in SEQ ID No. 25, and the DNA fragment shown in SEQ ID No. 28, where the positions 2-7 of SEQ ID No. 28 are the sequence of RBS, and the positions 15-686 of SEQ ID No. 28 are the nucleotide sequence of alkL.
  • PLB1a-mcrC-acc-alkL may express the mcrC protein shown in SEQ ID No. 23, the accBC protein shown in SEQ ID No. 26, the accDA protein shown in SEQ ID No. 27 and the alkL protein shown in SEQ ID No. 29.
  • Genomic DNA was extracted from Escherichia coli , and the puuE gene fragment was amplified with a primer puuE-F/puuE-R.
  • a vector pSB1s (the nucleotide sequence of the vector pSB1s was shown in SEQ ID No. 30) was digested with NcoI and XhoI, and a large fragment SB1s-NX of the vector was recovered.
  • the puuE gene fragment was ligated with the SB1s-NX fragment by the Gibson assembly method.
  • Escherichia coli DH5a was transformed and identified by a primer F105-F/puuE-R. Positive clones with the correct sequence of the target fragment were selected, and the obtained positive recombinant plasmid was named pSB1s-puuE.
  • Genomic DNA was extracted from Escherichia coli , a rocG gene fragment was amplified with a primer rocG-F/rocG-R, and the RBS sequence was introduced into the primer.
  • a large fragment SB1s-puuE-XP was obtained by digesting the vector pSB1s-puuE of the step (4) with XhoI and PstI.
  • the rocG gene fragment was ligated with the SB1s-puuE-XP fragment.
  • Escherichia coli DH5a was transformed and identified with a primer rocG-F/T-58. Positive clones with the correct sequence of the target fragment were selected to extract plasmid, and the obtained positive recombinant plasmid was named pSB1s-puuE-rocG.
  • PSB1s-puuE-rocG contains the puuE gene shown in SEQ ID No. 31 and the DNA fragment shown in SEQ ID No. 33, where the positions 2-7 of SEQ ID No. 33 are the sequence of RBS, and the positions 15-1289 of SEQ ID No. 33 are the sequence of the rocG gene.
  • PSB1s-puuE-rocG may express the puuE protein shown in SEQ ID No. 32 and the rocG protein shown in SEQ ID No. 34.
  • Competent cells were prepared from the strain FM07 of Example 1, and the pLB1a-mcrC-acc-alkL and pSB1s-puuE-rocG prepared in the above steps were introduced into FM07.
  • the cells were spread on an LB plate containing streptomycin and ampicillin and cultured overnight at 37° C. Positive clones containing the pLB1a-mcrC-acc-alkL and pSB1s-puuE-rocG were selected and named FM08.
  • FM08 was a strain obtained by transforming Escherichia coli BW25113 as the following (a1)-(a12):
  • Competent cells were prepared from the strain FM07, and plasmids pSB1s and pLB1a were introduced into the FM07 by the CaCl 2 method. The cells were spread on an LB plate containing streptomycin and ampicillin and cultured overnight at 37° C. Clones containing the plasmids pSB1s and pLB1a were selected and named FM00 as a control.
  • the A medium was a sterile medium consisting of solutes and a solvent, where the solvent was water, and the solutes and their concentrations were: 25 mM of NaHPO 4 , 25 mM of KH 2 PO 4 , 50 mM of NH 4 Cl, 5 mM of Na 2 SO 4 , 2 mM of MgSO 4 , 0.5% by volume of glycerol, 0.5% by mass of yeast powder, 50 ⁇ M of FeCl 3 , 20 ⁇ M of CaCl 2 , 10 ⁇ M of MnCl 2 , 10 ⁇ M of ZnSO 4 , 2 ⁇ M of CoCl 2 , 2 ⁇ M of NiCl 2 , 2 ⁇ M of Na 2 MO 4 , 2 ⁇ M of Na 2 SeO 3 and 2 ⁇ M of H 3 BO 3 .
  • the B medium was a sterile medium obtained by adding palmitic acid, a polyoxyethylene ether Brij58 emulsifier, Biotin and vitamin B6 to the A medium, where the mass percentage concentration of the palmitic acid was 0.5%, the mass percentage concentration of the polyoxyethylene ether Brij58 emulsifier was 0.2%, the concentration of the Biotin was 40 mg/L, and the concentration of the vitamin B6 was 10 mg/L.
  • the C medium was a sterile medium obtained by adding palmitic acid, the polyoxyethylene ether Brij58 emulsifier, Biotin, NaHCO 3 , vitamin B6 and glutamic acid to the A medium, where the mass percentage concentration of the palmitic acid was 1%, the mass percentage concentration of the polyoxyethylene ether Brij58 emulsifier was 0.2%, the concentration of the Biotin was 40 mg/L, the concentration of the NaHCO 3 was 20 mM, the concentration of the vitamin B6 was 10 mg/L, and the concentration of the glutamic acid was 2 mM.
  • the strain FM08 obtained in the step I and cultured overnight was cultured according to the following method: the strain was inoculated into 20 ml of the A medium containing streptomycin and kanamycin (the concentration of both streptomycin and kanamycin was 50 mg/L) at an inoculum size of 1%, and cultured at 37° C. for 12 h to collect the bacterial cells; the collected bacterial cells were transferred to 20 ml of the B medium containing streptomycin and kanamycin (the concentration of both streptomycin and kanamycin was 50 mg/L), and cultured at 37° C.
  • the OD 600 of the culture solution was 6; an arabinose inducer was added to the culture solution to allow the concentration of the arabinose inducer in the culture solution to be 0.2% by mass, the cells were cultured at 37° C. for 12 h, and the cells were collected to obtain FM08 cells.
  • FM00 was cultured in the A medium and the B medium free of streptomycin and kanamycin to obtain FM00 cells.
  • FM00 cells were substituted for FM08, and the other steps were unchanged, to obtain the FM00 sample to be tested.
  • the quantitative test results are shown in FIG. 1 .
  • the average content of ⁇ -alanine in the FM08 sample to be tested is 0.36 g/L (i.e., 0.36 g/5 ⁇ 10 12 cfu), and the mass percentage concentration of palmitic acid is 0.78%.
  • the average content of ⁇ -alanine in the FM00 sample to be tested is 0 mg/L, and the mass percentage concentration of palmitic acid is 0.89%.
  • the conversion rate of ⁇ -alanine prepared with palmitic acid as a substrate using FM08 is 16.36%, and ⁇ -alanine could not be obtained using FM00. It is indicated that ⁇ -alanine may be prepared using FM08.
  • a preparation method of FI08 was as follows, and primers used were shown in Table 3.
  • the genomic DNA of Corynebacterium glutamicum was extracted using a bacterial genome extraction kit (Tiangen Biotech Co., Ltd., product catalogue: DP302). Using the extracted total DNA of the Corynebacterium glutamicum genome as a template and accBC-F and accL-R as primers, a gene fragment accBC was amplified by PCR using high-fidelity TransStart FastPfu DNA polymerase, and the target fragment was recovered by agarose gel electrophoresis.
  • a gene fragment accDA was amplified by PCR using high-fidelity TransStart FastPfu DNA polymerase, and the target fragment was recovered by agarose gel electrophoresis.
  • a NheI site was introduced into the accDA-R primer to facilitate insertion of a subsequent gene fragment; and the 3′ terminal of the accBC fragment and the 5′ terminal of the accDA fragment introduced complementary sequences containing RBS by primers for the next round of assembly.
  • the acc fragment with a full-length gene sequence was further PCR-amplified, and the target fragment was recovered by agarose gel electrophoresis.
  • a vector pSB1s (the nucleotide sequence of the vector pSB1s was shown in SEQ ID No. 30) was digested with NcoI and XhoI, and a large fragment SB1s-NX of the vector was recovered. The above acc fragment was ligated with the SB1s-NX fragment by the Gibson assembly method. Escherichia coli DH5a competent cells were transformed by the CaCl 2 ) method. The cells were uniformly spread on an LB plate containing streptomycin and cultured overnight at 37° C. Clones were selected, and the clones capable of amplifying the target fragment were identified by a primer F-105/accL-R and sequenced.
  • the positive clones were selected, plasmids were extracted, and the obtained positive plasmid was named pSB1s-acc.
  • the pSB1s-acc contains a DNA fragment shown in positions 15-3259 of SEQ ID No. 25.
  • Genomic DNA was extracted from Marinobacter hydrocarbonoclasticus , the alkL gene fragment was amplified with a primer alkL-F/alkL-R′, and the RBS sequence was introduced into the primer.
  • a large fragment SB1s-acc-HS was obtained by digesting the vector pSB1s-acc with NheI and SpeI.
  • the alkL fragment was ligated with the SB1s-acc-HS fragment by the Gibson assembly method.
  • Escherichia coli DH5a was transformed and identified with a primer alkL-F/T-58. Positive clones with the correct sequence of the target fragment were selected, plasmids were extracted, and the obtained positive recombinant plasmid was named pSB1s-acc-alkL.
  • PSB1s-acc-alkL contains the DNA fragment shown in positions 15-3259 of SEQ ID No. 25 and the DNA fragment shown in SEQ ID No. 28.
  • the positions 2-7 of SEQ ID No. 28 are the sequence of RBS, and the positions 15-686 of SEQ ID No. 28 are the nucleotide sequence of alkL.
  • the pSB1s-acc-alkL may express the accBC protein shown in SEQ ID No. 26, the accDA protein shown in SEQ ID No. 27, and the alkL protein shown in SEQ ID No. 29.
  • the nucleotide sequence of the modified Chloroflexus aurantiacus malonyl-CoA reductase gene mcr gene was shown in SEQ ID No. 36, where the nucleotide sequence of the N-terminal domain of mcr was positions 1-1689 of SEQ ID No. 36, the nucleotide sequence of the C-terminal domain of mcr was positions 1704-3749 of SEQ ID No. 36, the RBS site was contained between the N-terminal domain and the C-terminal domain, and the sequence was positions 1691-1696 of SEQ ID No. 36.
  • the mcr gene sequence was obtained by whole gene synthesis and ligated to the pUC57 vector by the Gibson assembly method to obtain the vector pUC57-mcr.
  • a primer mcr-F/mcr-R was used for amplification to obtain the mcr gene fragment with the correct sequence.
  • the mcr gene fragment with the correct sequence obtained by the above (3-a) was subjected to agarose gel electrophoresis to recover the target fragment.
  • a vector pXB1k (the nucleotide sequence of the vector pXB1k was shown in SEQ ID No. 35) was digested with NcoI and XhoI, and a large fragment XB1k-NX of the vector was recovered.
  • the mcr gene fragment with the correct sequence obtained in the above (3-a) was ligated with the XB1k-NX fragment by the Gibson assembly method. Escherichia coli DH5a competent cells were transformed by the CaCl 2 method.
  • the cells were spread on an LB plate containing streptomycin and cultured overnight at 37° C. Clones were selected, and the clones capable of amplifying the target fragment were identified by a primer F-105/mcr-R and sequenced. The positive clones were selected, plasmids were extracted, and the obtained positive plasmid was named pXB1k-mcr.
  • PXB1k-mcr contains the DNA fragment shown in SEQ ID No. 36 and may express the mcr protein shown in SEQ ID No. 37.
  • Competent cells were prepared from the strain FM07 of Example 1, and the plasmids pSB1s-acc-alkL and pXB1k-mcr were transformed into FM07 by the CaCl 2 method. The cells were spread on an LB plate containing streptomycin and kanamycin and cultured overnight at 37° C. Positive clones containing the pSB1s-acc-alkL and pXB1k-mcr were selected and named FI08.
  • FI08 was a strain obtained by transforming Escherichia coli BW25113 as the following (b1)-(b10):
  • Competent cells were prepared from the strain FM07 of Example 1, and plasmids pSB1s and pXB1k were introduced into the FM07 by the CaCl 2 ) method. The cells were spread on an LB plate containing streptomycin and ampicillin and cultured overnight at 37° C. Clones containing the plasmids pSB1s and pXB1k were selected and named FC00 as a control.
  • the D medium was a sterile medium obtained by adding palmitic acid and a polyoxyethylene ether Brij58 emulsifier to the A medium of Example 2, where the mass percentage concentration of the palmitic acid was 0.5%, and the mass percentage concentration of the polyoxyethylene ether Brij58 emulsifier was 0.2%.
  • the E medium was a sterile medium obtained by adding palmitic acid, a polyoxyethylene ether Brij58 emulsifier, Biotin and NaHCO 3 to the A medium of Example 2, where the mass percentage concentration of the palmitic acid was 1%, the mass percentage concentration of the polyoxyethylene ether Brij58 emulsifier was 0.2%, the concentration of the Biotin was 40 mg/L, and the concentration of the NaHCO 3 was 20 mM.
  • the strain FI08 obtained in the step I and cultured overnight was cultured according to the following method: the strain was inoculated into 20 ml of the A medium containing streptomycin and kanamycin (the concentration of both streptomycin and kanamycin was 50 mg/L) of Example 2 at an inoculum size of 1%, and cultured at 37° C. for 12 h to collect the bacterial cells; the collected cells were transferred to 20 ml of the D medium containing streptomycin and kanamycin (the concentration of both streptomycin and kanamycin was 50 mg/L), and cultured at 37° C.
  • a culture solution for 6 h to obtain a culture solution; the OD 600 of the culture solution was 6; an arabinose inducer was added to the culture solution to allow the concentration of the arabinose inducer in the culture solution to be 0.2% by mass, the cells were cultured at 37° C. for 12 h, and the cells were collected to obtain FI08 cells.
  • FC00 was cultured in the A medium and the D medium free of streptomycin and kanamycin to obtain FC00 cells.
  • FC00 cells were substituted for FI08, and the other steps were unchanged, to obtain the FC00 sample to be tested.
  • the quantitative test results are shown in FIG. 2 .
  • the average content of 3-hydroxypropionic acid in the FI08 sample to be tested is 0.539 g/L (i.e., 0.539 g/5 ⁇ 10 12 cfu), and the mass percentage concentration of palmitic acid is 0.81%.
  • the average content of 3-hydroxypropionic acid in the FC00 sample to be tested is 0 mg/L, and the mass percentage concentration of palmitic acid is 0.91%.
  • the conversion rate of 3-hydroxypropionic acid prepared with palmitic acid as a substrate using FI08 is 28.37%, and 3-hydroxypropionic acid could not be obtained using FC00. It is indicated that 3-hydroxypropionic acid may be prepared using FI08.
  • a preparation method of FA11 was as follows, and primers used were shown in Table 4.
  • the Escherichia coli gene fragment having the iclR knockout trait was derived from Escherichia coli strain JW3978.
  • JW3978 was a product of the National Institute of Genetics (NIG, Japan). According to the P1 phage preparation method of the step (1) of Example 1, the strain JW3978 was substituted for the JW1176 strain, and the phage P1vir iclR containing the Escherichia coli gene fragment having the iclR knockout trait was obtained.
  • the recombinant strain FM07 of Example 1 was substituted for Escherichia coli BW25113 according to the method of the step (1) in Example 1.
  • An iclR-IF/iclR-IR primer was used for PCR amplification and identification (an amplified target band of 1700 bp was positive), and positive clones were selected and named FA08-Kan.
  • FA08-Kan was substituted for FM01-Kan, and the kanamycin resistance of the strain was eliminated.
  • the iclR-IF/iclR-IR primer was used for PCR amplification and identification (an amplified target band of 400 bp was positive), and positive clones were selected and named FA08.
  • FA08 is a strain obtained by knocking out the iclR gene of FM07 in Example 1.
  • the iclR gene encodes the protein shown in SEQ ID No. 39, and the coding sequence of the iclR gene is shown in SEQ ID No. 38.
  • IclR-IF/iclR-IR obtains a fragment of about 400 bp by amplification from the genomic DNA of FA08, and obtains a fragment of about 1200 bp by amplification from the genomic DNA of FM07.
  • the primer binding positions of the iclR-IF and iclR-IR are the upstream region and the downstream region of the iclR gene of Escherichia coli BW25113, respectively.
  • the results of sequencing analysis show that there is no iclR gene on the genome of FA08, and FA08 is a strain obtained by knocking out the iclR gene of FM07 in Example 1.
  • the Escherichia coli gene fragment having the sucA knockout trait was derived from Escherichia coli strain JW0715.
  • JW0715 was a product of the National Institute of Genetics (NIG, Japan). According to the P1 phage preparation method of the step (1) of Example 1, the strain JW0715 was substituted for the JW1176 strain, and the phage P1vir sucA containing the Escherichia coli gene fragment having the sucA knockout trait was obtained.
  • FA08 was substituted for Escherichia coli BW25113 according to the method of the step (1) in Example 1.
  • a sucA-IF/sucA-IR primer was used for PCR amplification and identification (an amplified target band of 1700 bp was positive), and positive clones were selected and named FA00-Kan.
  • FA09 is a strain obtained by knocking out the sucA gene of FA08.
  • the sucA gene encodes the protein shown in SEQ ID No. 41, and the coding sequence of the sucA gene is shown in SEQ ID No. 40.
  • SucA-IF/sucA-IR obtains a fragment of about 400 bp by amplification from the genomic DNA of FA09, and obtains a fragment of about 3200 bp by amplification from the genomic DNA of FM08.
  • the primer binding positions of the sucA-IF and sucA-IR are the upstream region and the downstream region of the sucA gene of Escherichia coli BW25113, respectively.
  • the results of sequencing analysis show that there is no sucA gene in the genome of FA00, and FA09 is a strain obtained by knocking out the sucA gene of FA08.
  • the Escherichia coli constitutive promoter P CPA1 was substituted for the promoter of the glyoxylate pathway aceBA gene cluster (the gene cluster contained the aceB gene and the aceA gene), and recombinant Escherichia coli FA10 was obtained.
  • the specific steps were as follows:
  • the pKD46 plasmid was transformed into the FA09 strain obtained in the previous step according to the method of the step (2) of Example 1 to obtain recombinant Escherichia coli FA09/pKD46 containing the plasmid pKD46, and then FA09/pKD46 competent cells were prepared.
  • an aceBAup-kan-P CPA1 -aceBAdown fragment was amplified using a primer aceBA-PF/aceBA-PR.
  • the sequence of the aceBAup-kan-P CPA1 -aceBAdown fragment was SEQ ID No. 42 in the sequence listing, and the fragment contained (a) a promoter upstream homologous arm aceBAup of the aceBA gene cluster, the nucleotide sequence of which was positions 1-51 of SEQ ID No. 42; (b) a kanamycin resistance gene (LOXP-kan-LOXP) flanked by LOXP, the nucleotide sequence of which was positions 52-1492 of SEQ ID No.
  • LOXP-kan-LOXP kanamycin resistance gene
  • the above aceBAup-kan-P CPA1 -aceBAdown fragment was electroporated into the FA09/pKD46 competent cells prepared in (3-a), the cells were placed in an LB plate containing kanamycin (concentration: 50 ⁇ g/ml) overnight at 37° C., and clones were selected.
  • An aceBA-PIF/aceBA-PIR primer was used for PCR amplification and identification (an amplified target band of about 2,000 bp was positive, and an amplified target band of about 400 bp was negative), and the positive clones were selected and named FA10-kan.
  • the primer binding positions were the upstream and downstream regions of the promoter of the aceBA gene cluster of Escherichia coli BW25113, respectively.
  • the results of sequencing analysis indicate that the genome of FA10-kan contains the aceBAup-kan-P CPA1 -aceBAdown fragment of the step (3-b).
  • the kanamycin resistance of FA10-kan was eliminated using the pCP20 plasmid according to the method of the step (2) of Example 1.
  • the aceBA-PIF/aceBA-PIR primer was used for PCR amplification and identification (an amplified target band of about 600 bp was positive, and an amplified target band of about 2,000 or 400 bp was negative), and positive clones were selected and named FA10.
  • FA10 is a strain obtained by substituting the constitutive promoter P CPA1 for the promoter of the aceBA gene cluster of FA09.
  • the aceB gene in the aceBA gene cluster encodes the protein shown in SEQ ID No. 44
  • the coding sequence of the aceB gene is shown in SEQ ID No. 43
  • the aceA gene encodes the protein shown in SEQ ID No. 46
  • the coding sequence of the aceA gene is shown in SEQ ID No. 45.
  • the results of sequencing analysis indicate that the constitutive promoter P CPA1 is substituted for the promoter of aceBA gene cluster on the genome of FA10, and the expression of the aceB gene and the aceA gene in the aceBA gene cluster is initiated by the P CPA1 .
  • the genomic DNA of Escherichia coli was extracted using a bacterial genome extraction kit (Tiangen Biotech Co., Ltd., product catalogue: DP302). Using the extracted total DNA of the Escherichia coli genome as a template and aspC-F and aspC-R as primers, PCR amplification was carried out using high-fidelity TransStart FastPfu DNA polymerase (Beijing TransGen Biotech Co., Ltd., product catalogue: AP221) to obtain a gene fragment aspC of the correct sequence.
  • TransStart FastPfu DNA polymerase Beijing TransGen Biotech Co., Ltd., product catalogue: AP221
  • a vector pLB1a (the nucleotide sequence of the vector pLB1a was shown in SEQ ID No. 24) was digested with NcoI and XhoI, and a large fragment LB1a-NX of the vector was recovered.
  • the gene fragment aspC with the correct sequence obtained in the above step was ligated with the LB1a-NX fragment by the Gibson assembly method.
  • Escherichia coli DH5a competent cells were transformed by the CaCl 2 ) method. The cells were uniformly spread on an LB plate containing ampicillin and cultured overnight at 37° C. Clones were selected and identified by a primer F105-F/aspC-R. The positive clones with the correct sequence of the target fragment were selected, and the obtained positive recombinant plasmid was named pLB1a-aspC.
  • Genomic DNA was extracted from Escherichia coli , a gdhA gene fragment was amplified with a primer gdhA-F/gdhA-R, and the RBS sequence was introduced into the primer.
  • a large fragment LB1a-aspC-XP was obtained by digesting the vector pLB1a-aspC with XhoI and SpeI.
  • the gdhA gene fragment was ligated with the LB1a-aspC-XP fragment by the Gibson assembly method.
  • Escherichia coli DH5a was transformed and identified by a primer gdhA-F/T58-R. Positive clones with the correct sequence of the target fragment were selected, and the obtained positive recombinant plasmid was named pLB1a-aspC-gdhA.
  • Genomic DNA was extracted from Marinobacter hydrocarbonoclasticus , the alkL gene fragment was amplified with a primer alkL-F′′/alkL-R′′, and the RBS sequence was introduced into the primer.
  • a large fragment LB1a-aspC-gdhA-PE was obtained by digesting the vector pLB1a-aspC-gdhA with SpeI and EcoRI.
  • the alkL gene fragment was ligated with the LB1a-aspC-gdhA-PE fragment by the Gibson assembly method.
  • Escherichia coli DH5a was transformed and identified by the primer alkL-F/T58-R. Positive clones with the correct sequence of the target fragment were selected, and the obtained positive recombinant plasmid was named pLB1a-aspC-gdhA-alkL.
  • the pLB1a-aspC-gdhA-alkL contains the aspC gene shown in SEQ ID No. 47, the gdhA gene shown in SEQ ID No. 49, and the DNA fragment (containing the alkL gene) shown in SEQ ID No. 28.
  • the positions 2-7 of SEQ ID No. 49 are the sequence of RBS, and the positions 15-1358 of SEQ ID No. 49 are the sequence of the gdhA gene.
  • the pLB1a-aspC-gdhA-alkL may express the aspC protein shown in SEQ ID No. 48, the gdhA protein shown in SEQ ID No. 50, and the alkL protein shown in SEQ ID No. 29.
  • the L-aspartate- ⁇ -decarboxylase gene panD gene of Tribolium castaneum was obtained by whole gene synthesis and ligated to the pUC57 vector to obtain a vector pUC57-panD.
  • the nucleotide sequence of the panD gene was shown in SEQ ID No. 51.
  • panD-F and panD-R as primers and vector pUC57-panD plasmid as a template
  • a panD gene fragment was amplified by PCR using high-fidelity TransStart FastPfu DNA polymerase.
  • a vector pXB1k (the nucleotide sequence of the vector pXB1k was shown in SEQ ID No.
  • panD gene fragment was ligated with the XB1k-NX fragment by the Gibson assembly method. Escherichia coli DH5a was transformed, the cells were spread on an LB plate containing kanamycin and cultured at 37° C. overnight, and clones were selected. A primer F105-F/panD-R was used for identification. The positive clones with the correct sequence of the target fragment were selected, plasmids were extracted, and the obtained positive recombinant plasmid was named pXB1k-panD.
  • the pXB1k-panD contains the panD gene shown in SEQ ID No. 51 and may express the panD protein shown in SEQ ID No. 52.
  • Competent cells were prepared from the strain FA10 obtained in step (3), and the plasmids pLB1a-aspC-gdhA-alkL and pXB1k-panD were transformed into FA10 by the CaCl 2 method. The cells were spread on an LB plate containing ampicillin and kanamycin and cultured overnight at 37° C. Positive clones containing the pLB1a-aspC-gdhA-alkL and pXB1k-panD were selected and named FA11.
  • FA11 was a strain obtained by transforming Escherichia coli BW25113 as the following (c1)-(c14):
  • Competent cells were prepared from the strain FA10, and plasmids pLB1a and pXB1k were transformed into the FA10 by the CaCl 2 ) method. The cells were spread on an LB plate containing ampicillin and kanamycin and cultured overnight at 37° C. Positive clones containing pLB1a and pXB1k were selected and named FA00.
  • the F medium was a sterile medium obtained by adding palmitic acid, a polyoxyethylene ether Brij58 emulsifier and vitamin B6 to the A medium of Example 2, where the mass percentage concentration of the palmitic acid was 0.5%, the mass percentage concentration of the polyoxyethylene ether Brij58 emulsifier was 0.2%, and the concentration of the vitamin B6 was 40 mg/L.
  • the G medium was a sterile medium obtained by adding palmitic acid, a polyoxyethylene ether Brij58 emulsifier, vitamin B6 and glutamic acid to the A medium of Example 2, where the mass percentage concentration of the palmitic acid was 1%, the mass percentage concentration of the polyoxyethylene ether Brij58 emulsifier was 0.2%, the concentration of the vitamin B6 was 10 mg/L, and the concentration of the glutamic acid was 2 mM.
  • the strain FA11 obtained in the step I and cultured overnight was cultured according to the following method.
  • the strain was inoculated into 20 ml of the A medium containing streptomycin and kanamycin (the concentration of both streptomycin and kanamycin was 50 mg/L) of Example 2 at an inoculum size of 1%, and cultured at 37° C. for 12 h to collect the bacterial cells; the collected cells were transferred to 20 ml of the F medium containing streptomycin and kanamycin (the concentration of both streptomycin and kanamycin was 50 mg/L), and cultured at 37° C.
  • FA00 was cultured in the A medium and the F medium free of streptomycin and kanamycin to obtain FA00 cells.
  • the quantitative test results are shown in FIG. 3 .
  • the average content of ⁇ -alanine in the FA11 sample to be tested is 4.2 g/L (i.e., 4.2 g/5 ⁇ 10 12 cfu), and the mass percentage concentration of palmitic acid is 0.31%.
  • the average content of ⁇ -alanine in the FA00 sample to be tested is 0 g/L, and the mass percentage concentration of palmitic acid is 0.90%.
  • the conversion rate of ⁇ -alanine prepared with palmitic acid as a substrate using FA11 is 60.87%, and ⁇ -alanine could not be obtained using FA00. It is indicated that ⁇ -alanine may be prepared using FA11.
  • the present invention synthesizes 3-hydroxypropionic acid from a fatty acid as a raw material, and the theoretical conversion rate reaches 217.86%, which is significantly higher than that from glucose (the theoretical conversion rate is 100%).
  • the present invention also prepares recombinant bacteria for producing the 3-hydroxypropionic acid from a fatty acid as a raw material.
  • the recombinant bacteria may be used to produce 3-hydroxypropionic acid by microbial fermentation and biotransformation using a fatty acid raw material obtained from crude oil processing products, waste oil, or the like at a low price. Therefore, the use of the fatty acid raw material to synthesize 3-hydroxypropionic acid has a potential cost advantage.
  • the conversion rate of 3-hydroxypropionic acid produced by using the recombinant bacteria of the present invention from a fatty acid as a raw material is 28.37%, indicating that 3-hydroxypropionic acid may be produced using the recombinant bacteria of the present invention.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
US16/604,854 2017-04-14 2018-04-12 Recombinant bacteria for producing 3-hydroxy propionic acid, preparation method therefor, and applications thereof Active 2038-07-14 US11155839B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710247568.7 2017-04-14
CN201710247568.7A CN108728471B (zh) 2017-04-14 2017-04-14 产3-羟基丙酸的重组菌及其制备方法与应用
PCT/CN2018/082736 WO2018188617A1 (fr) 2017-04-14 2018-04-12 Bactéries recombinées pour produire de l'acide 3-hydroxypropionique, procédé de préparation associé et applications associées

Publications (2)

Publication Number Publication Date
US20200157584A1 US20200157584A1 (en) 2020-05-21
US11155839B2 true US11155839B2 (en) 2021-10-26

Family

ID=63793155

Family Applications (1)

Application Number Title Priority Date Filing Date
US16/604,854 Active 2038-07-14 US11155839B2 (en) 2017-04-14 2018-04-12 Recombinant bacteria for producing 3-hydroxy propionic acid, preparation method therefor, and applications thereof

Country Status (6)

Country Link
US (1) US11155839B2 (fr)
EP (1) EP3613844A4 (fr)
JP (1) JP7261222B2 (fr)
KR (1) KR102646320B1 (fr)
CN (1) CN108728471B (fr)
WO (1) WO2018188617A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024144285A1 (fr) * 2022-12-28 2024-07-04 씨제이제일제당 (주) Micro-organismes dans lesquels une trans-hydrogénase de nucléotide pyridine soluble dans l'eau étrangère est introduite, et procédé de production de l-tryptophane l'utilisant

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111197054B (zh) * 2018-11-20 2021-09-07 中国科学院微生物研究所 重组恶臭假单胞菌的构建及其在生产丙酸中的应用
CN109593697B (zh) * 2018-12-18 2022-07-12 江苏师范大学 一种产3-羟基丙酸的重组假单胞菌及其构建方法
CN109749936A (zh) * 2019-01-16 2019-05-14 徐州工程学院 一种3-羟基丙酸产生菌株的筛选方法
CN109852605A (zh) * 2019-01-16 2019-06-07 徐州工程学院 一种诱变筛选高产3-羟基丙酸菌株的方法
CN112410389B (zh) * 2019-08-23 2023-07-18 中国科学院微生物研究所 支链α-酮酸脱氢酶复合体在制备丙二酸单酰辅酶A中的应用
CN110564757A (zh) * 2019-09-27 2019-12-13 华东理工大学 利用乙酸或其盐生产3-羟基丙酸的代谢工程大肠杆菌菌株的构建方法及应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102695799A (zh) 2009-09-27 2012-09-26 Opx生物工艺学公司 用于制备3-羟基丙酸和其它产物的方法
CN103497922A (zh) 2013-09-10 2014-01-08 中国科学院青岛生物能源与过程研究所 一种联产3-hp和p3hp的重组肺炎克雷伯氏菌及其制备方法和应用
CN103898034A (zh) 2012-12-27 2014-07-02 中国科学院青岛生物能源与过程研究所 一种生物法合成聚3-羟基丙酸的方法
CN105189757A (zh) 2013-03-15 2015-12-23 嘉吉公司 乙酰辅酶a羧化酶突变

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102625846B (zh) * 2009-04-30 2016-08-03 基因组股份公司 用于生产1,3-丁二醇的生物
WO2012129450A1 (fr) 2011-03-22 2012-09-27 Opx Biotechnologies, Inc. Production microbienne de produits chimiques, et compositions, procédés et systèmes associés
KR101860442B1 (ko) * 2011-06-27 2018-05-24 삼성전자주식회사 3-하이드록시프로피온산의 생산을 위한 유전자 조작
CN102392056A (zh) * 2011-12-09 2012-03-28 华东理工大学 一种基因工程菌株及利用该菌株生产二羟基丙酮的方法
JPWO2013137277A1 (ja) 2012-03-14 2015-08-03 株式会社日本触媒 ３−ヒドロキシプロピオン酸の製造方法、遺伝子組換え微生物、並びに前記方法を利用したアクリル酸、吸水性樹脂、アクリル酸エステル、およびアクリル酸エステル樹脂の製造方法
US10704064B2 (en) * 2014-08-29 2020-07-07 Sk Innovation Co., Ltd. Recombinant yeast producing 3-hydroxypropionic acid and method for producing 3-hydroxypropionic acid using the same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102695799A (zh) 2009-09-27 2012-09-26 Opx生物工艺学公司 用于制备3-羟基丙酸和其它产物的方法
CN103898034A (zh) 2012-12-27 2014-07-02 中国科学院青岛生物能源与过程研究所 一种生物法合成聚3-羟基丙酸的方法
CN105189757A (zh) 2013-03-15 2015-12-23 嘉吉公司 乙酰辅酶a羧化酶突变
CN103497922A (zh) 2013-09-10 2014-01-08 中国科学院青岛生物能源与过程研究所 一种联产3-hp和p3hp的重组肺炎克雷伯氏菌及其制备方法和应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
International Search Report dated Jun. 28, 2018 in PCT/CN2018/082736.
PCT/CN2018/082736 , Written opinion (English Translation), dated Jun. 28, 2018 (Year: 2018). *
Yang P, et al. "Biosynthesis of poly(3-hydroxypropionate) and its copolymers" (in Chinese). Chin Sci Bull (Chin Ver), 2014, 59: 2137-2144.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024144285A1 (fr) * 2022-12-28 2024-07-04 씨제이제일제당 (주) Micro-organismes dans lesquels une trans-hydrogénase de nucléotide pyridine soluble dans l'eau étrangère est introduite, et procédé de production de l-tryptophane l'utilisant

Also Published As

Publication number Publication date
WO2018188617A1 (fr) 2018-10-18
JP7261222B2 (ja) 2023-04-19
US20200157584A1 (en) 2020-05-21
KR102646320B1 (ko) 2024-03-11
EP3613844A4 (fr) 2021-07-07
CN108728471B (zh) 2020-01-31
EP3613844A1 (fr) 2020-02-26
KR20200005552A (ko) 2020-01-15
CN108728471A (zh) 2018-11-02
JP2020516316A (ja) 2020-06-11

Similar Documents

Publication Publication Date Title
US11155839B2 (en) Recombinant bacteria for producing 3-hydroxy propionic acid, preparation method therefor, and applications thereof
Pan et al. Synthetic biology toolkit for engineering Cupriviadus necator H16 as a platform for CO2 valorization
RU2639564C2 (ru) Модифицированные микроорганизмы и способы получения бутадиена с их применением
CN108728470B (zh) 产β-丙氨酸的重组菌及其构建方法与应用
JP2007517517A (ja) １，２−プロパンジオールの産生のための発展型微生物
JP7317255B1 (ja) Ｐｈａ生産量の高い遺伝子組換え細菌及びその構築方法
AU2012214255A1 (en) Cells and methods for producing isobutyric acid
KR20220085818A (ko) 보조인자를 증가시키기 위한 미생물 및 방법
US20140134690A1 (en) Microbes and methods for producing 1-propanol
WO2023225582A2 (fr) Cellules bactériennes recombinées et méthodes de production de poly(3-hydroxybutyrate-co-3-hydroxyvalérate)
CN104974946A (zh) 耐高渗透压的重组大肠杆菌及其应用
WO2023246071A1 (fr) Mutant mrec et son utilisation dans la production par fermentation de l-valine
US20220380822A1 (en) Application of branched-chain a-ketoacid dehydrogenase complex in preparation of malonyl coenzyme a
CN108728469B (zh) 重组大肠杆菌工程菌的构建及其在生产β-丙氨酸中的应用
JP2014023528A (ja) 改変微生物及び該改変微生物を利用した１，４−ブタンジオールの生産方法
KR102683624B1 (ko) 기능적 dna 서열의 안정화된 카피 수를 갖는 미생물 및 관련 방법
CN116064362A (zh) 一种利用葡萄糖从头合成12-氨基月桂酸的基因工程菌及其构建和应用
CN120442512A (zh) 用于合成甘氨酸的重组大肠杆菌及其应用
WO2025220580A1 (fr) Mutant de bactérie hydrogenophilus ayant une capacité de production crotonyl-coa améliorée
WO2025220434A1 (fr) Mutant de bactérie oxydant l'hydrogène auxotrophe à la biotine
KR20230173870A (ko) 에탄올 및 글리세롤을 폴리하이드록시알카노에이트로 전환하기 위한 재조합 슈도모나스 푸티다 바이오촉매의 개발
CN120173849A (zh) 一种用于生物发酵产生hmb的工程菌及其应用
CN119979428A (zh) 利用脂肪酸合成l-高丝氨酸和l-苏氨酸的重组菌及其应用
CN120738094A (zh) 生成丙酮酸的重组大肠杆菌及其制备方法
CN120349947A (zh) 用于合成hmb的重组菌株及其应用

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: AWAITING TC RESP., ISSUE FEE NOT PAID

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 4